252 related articles for article (PubMed ID: 34030541)
1. Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer.
Cohen AT; Keshishian A; Lee T; Rosenblatt L; Hlavacek P; Sah J; Luo X
Curr Med Res Opin; 2021 Sep; 37(9):1467-1482. PubMed ID: 34030541
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
Adv Ther; 2021 Nov; 38(11):5519-5533. PubMed ID: 34570310
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity.
Cohen A; Sah J; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33429844
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer.
Cohen A; Noxon V; Dhamane A; Bruette R; Shah S; Hines DM; Alfred T; Luo X
Thromb Res; 2023 Jun; 226():117-126. PubMed ID: 37146438
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences.
Cohen AT; Sah J; Dhamane AD; Hines DM; Lee T; Rosenblatt L; Emir B; Keshishian A; Yuce H; Luo X
Adv Ther; 2023 Apr; 40(4):1705-1735. PubMed ID: 36811795
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal disease.
Cohen AT; Noxon V; Dhamane AD; Shah S; Hines DM; Alfred T; Chaves J; Luo X
Curr Med Res Opin; 2024 Mar; 40(3):545-553. PubMed ID: 38332714
[TBL] [Abstract][Full Text] [Related]
8. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population.
Guo JD; Hlavacek P; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Thromb Res; 2021 Feb; 198():163-170. PubMed ID: 33348190
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Delinger R; Yuce H; Luo X
Thromb Haemost; 2022 Jun; 122(6):926-938. PubMed ID: 34963185
[TBL] [Abstract][Full Text] [Related]
11. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
[No Abstract] [Full Text] [Related]
12. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Rutjes AW; Porreca E; Candeloro M; Valeriani E; Di Nisio M
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD008500. PubMed ID: 33337539
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.
Recio-Boiles A; Veeravelli S; Vondrak J; Babiker HM; Scott AJ; Shroff RT; Patel H; Elquza E; McBride A
World J Gastrointest Oncol; 2019 Oct; 11(10):866-876. PubMed ID: 31662825
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
[TBL] [Abstract][Full Text] [Related]
16. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
17. Pentasaccharides for the prevention of venous thromboembolism.
Dong K; Song Y; Li X; Ding J; Gao Z; Lu D; Zhu Y
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005134. PubMed ID: 27797404
[TBL] [Abstract][Full Text] [Related]
18. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.
Weycker D; Wygant GD; Guo JD; Lee T; Luo X; Rosenblatt L; Mardekian J; Atwood M; Hanau A; Cohen AT
Blood Adv; 2020 Jan; 4(2):432-439. PubMed ID: 31990332
[TBL] [Abstract][Full Text] [Related]
19. Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban.
Houghton DE; Casanegra AI; Peterson LG; Cochuyt J; Hodge DO; Vlazny D; McBane RD; Froehling D; Wysokinski WE
Am J Hematol; 2020 Jul; 95(7):817-823. PubMed ID: 32267011
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.
Cohen AT; Sah J; Dhamane AD; Lee T; Rosenblatt L; Hlavacek P; Emir B; Keshishian A; Yuce H; Luo X
PLoS One; 2022; 17(9):e0274969. PubMed ID: 36149864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
